Nrf2, the master redox switch: The Achilles' heel of ovarian cancer?

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 2, 2014, Pages 494-509

  van der Wijst, Monique G P ^a   Brown, Robert ^b   Rots, Marianne G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer therapy; Mutations; Nrf2; Ovarian cancer; Oxidative stress; Reactive oxygen species

Indexed keywords

B RAF KINASE; BLEOMYCIN; BRCA1 PROTEIN; BRUSATOL; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; K RAS PROTEIN; PROCYANIDIN DERIVATIVE; PROTEIN P53; TRANSCRIPTION FACTOR NRF2; NFE2L2 PROTEIN, HUMAN;

BRAF GENE; CANCER GRADING; CANCER SURGERY; CARCINOGENESIS; DNA DAMAGE; DOWN REGULATION; EPIGENETICS; ERBB2 GENE; GENE ACTIVATION; GENE ACTIVITY; GENE CONTROL; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; KRAS GENE; NONHUMAN; NRF2 GENE; ONCOGENE; OVARIAN CANCER CELL LINE; OVARY CANCER; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; RNA TRANSLATION; TP53 GENE; TUMOR SUPPRESSOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; FEMALE; GENETICS; MUTATION; OVARIAN NEOPLASMS; PHYSIOLOGY;

ANIMALS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; NF-E2-RELATED FACTOR 2; ONCOGENES; OVARIAN NEOPLASMS; OXIDATIVE STRESS;

EID: 84907942610     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.09.004     Document Type: Review

References (198)

1. Murphy M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417:1-13.
2. Kehrer J.P. The Haber-Weiss reaction and mechanisms of toxicity. Toxicol. 2000, 149:43-50.
3. D'Autreaux B., Toledano M.B. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol. 2007, 8:813-824.
4. Khansari N., Shakiba Y., Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Patents Inflamm. Allergy Drug Discov. 2009, 3:73-80.
5. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
6. Trachootham D., Lu W., Ogasawara M.A., Nilsa R.D., Huang P. Redox regulation of cell survival. Antioxid. Redox Signal. 2008, 10:1343-1374.
7. Kansanen E., Jyrkkanen H.K., Levonen A.L. Activation of stress signaling pathways by electrophilic oxidized and nitrated lipids. Free Radic. Biol. Med. 2012, 52:973-982.
8. Kang M.I., Kobayashi A., Wakabayashi N., Kim S.G., Yamamoto M. Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2046-2051.
9. Taguchi K., Motohashi H., Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011, 16:123-140.
10. Baird L., Swift S., Lleres D., Dinkova-Kostova A.T. Monitoring Keap1-Nrf2 interactions in single live cells. Biotechnol. Adv. 2014, 32:1133-1144.
11. Niture S.K., Khatri R., Jaiswal A.K. Regulation of Nrf2-an update. Free Radic. Biol. Med. 2014, 66:36-44.
12. Katsuoka F., Motohashi H., Ishii T., Aburatani H., Engel J.D., Yamamoto M. Genetic evidence that small maf proteins are essential for the activation of antioxidant response element-dependent genes. Mol. Cell. Biol. 2005, 25:8044-8051.
13. Malhotra D., Portales-Casamar E., Singh A., Srivastava S., Arenillas D., Happel C., Shyr C., Wakabayashi N., Kensler T.W., Wasserman W.W., Biswal S. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 2010, 38:5718-5734.
14. Niture S.K., Jain A.K., Shelton P.M., Jaiswal A.K. Src subfamily kinases regulate nuclear export and degradation of transcription factor Nrf2 to switch off Nrf2-mediated antioxidant activation of cytoprotective gene expression. J. Biol. Chem. 2011, 286:28821-28832.
15. MacLeod A.K., McMahon M., Plummer S.M., Higgins L.G., Penning T.M., Igarashi K., Hayes J.D. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 2009, 30:1571-1580.
16. Reichard J.F., Sartor M.A., Puga A. BACH1 is a specific repressor of HMOX1 that is inactivated by arsenite. J. Biol. Chem. 2008, 283:22363-22370.
17. McMahon M., Thomas N., Itoh K., Yamamoto M., Hayes J.D. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J. Biol. Chem. 2004, 279:31556-31567.
18. Chowdhry S., Zhang Y., McMahon M., Sutherland C., Cuadrado A., Hayes J.D. Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 2013, 32:3765-3781.
19. Ziech D., Franco R., Pappa A., Panayiotidis M.I. Reactive oxygen species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis. Mutat. Res. 2011, 711:167-173.
20. Miguel d.M., Cordero M. Chapter 22: oxidative therapy against cancer. Oxidative Stress and Diseases, InTech 2012, (Available from: http://www.intechopen.com/books/oxidative-stress-and-diseases/oxidative-therapy-against-cancer). 10.5772/33251. V. Lushchak, D. Gospodaryov (Eds.).
21. Geismann C., Arlt A., Sebens S., Schafer H. Cytoprotection "gone astray": Nrf2 and its role in cancer. Onco. Targets Ther. 2014, 7:1497-1518.
22. Lau A., Villeneuve N.F., Sun Z., Wong P.K., Zhang D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res. 2008, 58:262-270.
23. Stacy D.R., Ely K., Massion P.P., Yarbrough W.G., Hallahan D.E., Sekhar K.R., Freeman M.L. Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck 2006, 28:813-818.
24. Bauer A.K., Hill T., Alexander C.M. The involvement of NRF2 in lung cancer. Oxidative Med. Cell. Longev. 2013, 2013:746432.
25. Jiang T., Chen N., Zhao F., Wang X.J., Kong B., Zheng W., Zhang D.D. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010, 70:5486-5496.
26. Wang J., Zhang M., Zhang L., Cai H., Zhou S., Zhang J., Wang Y. Correlation of Nrf2, HO-1, and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival. J. Surg. Res. 2010, 164:e99-e105.
27. Frohlich D.A., McCabe M.T., Arnold R.S., Day M.L. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene 2008, 27:4353-4362.
28. Yu S., Khor T.O., Cheung K.L., Li W., Wu T.Y., Huang Y., Foster B.A., Kan Y.W., Kong A.N. Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. PLoS ONE 2010, 5:e8579.
29. Eades G., Yang M., Yao Y., Zhang Y., Zhou Q. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J. Biol. Chem. 2011, 286:40725-40733.
30. Yang M., Yao Y., Eades G., Zhang Y., Zhou Q. MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism. Breast Cancer Res. Treat. 2011, 129:983-991.
31. Singh B., Ronghe A.M., Chatterjee A., Bhat N.K., Bhat H.K. MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis. Carcinogenesis 2013, 34:1165-1172.
32. Martinez V.D., Vucic E.A., Thu K.L., Pikor L.A., Hubaux R., Lam W.L. Unique pattern of component gene disruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in serous ovarian cancer. BioMed. Res. Int. 2014, 2014:10.
33. Barbano R., Muscarella L.A., Pasculli B., Valori V.M., Fontana A., Coco M., la Torre A., Balsamo T., Poeta M.L., Marangi G.F., Maiello E., Castelvetere M., Pellegrini F., Murgo R., Fazio V.M., Parrella P. Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics 2013, 8:105-112.
34. Shibata T., Kokubu A., Gotoh M., Ojima H., Ohta T., Yamamoto M., Hirohashi S. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008, 135:1358-1368. (1368.e1-4).
35. Wong T.F., Yoshinaga K., Monma Y., Ito K., Niikura H., Nagase S., Yamamoto M., Yaegashi N. Association of keap1 and nrf2 genetic mutations and polymorphisms with endometrioid endometrial adenocarcinoma survival. Int. J. Gynecol. Cancer 2011, 21:1428-1435.
36. Zhang P., Singh A., Yegnasubramanian S., Esopi D., Kombairaju P., Bodas M., Wu H., Bova S.G., Biswal S. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol. Cancer Ther. 2010, 9:336-346.
37. Khor T.O., Fuentes F., Shu L., Paredes-Gonzalez X., Yang A.Y., Liu Y., Smiraglia D.J., Yegnasubramanian S., Nelson W.G., Kong A.N. Epigenetic DNA methylation of anti-oxidative stress regulator Nrf2 in human prostate cancer. Cancer Prev. Res. Sep 29 2014, (Epub ahead of print).
38. Hast B.E., Cloer E.W., Goldfarb D., Li H., Siesser P.F., Yan F., Walter V., Zheng N., Hayes D.N., Major M.B. Cancer-derived mutations in KEAP1 Impair NRF2 degradation but not ubiquitination. Cancer Res. 2014, 74:808-817.
39. Kim Y.R., Oh J.E., Kim M.S., Kang M.R., Park S.W., Han J.Y., Eom H.S., Yoo N.J., Lee S.H. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J. Pathol. 2010, 220:446-451.
40. Shibata T., Ohta T., Tong K.I., Kokubu A., Odogawa R., Tsuta K., Asamura H., Yamamoto M., Hirohashi S. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13568-13573.
41. Hayes J.D., McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem. Sci. 2009, 34:176-188.
42. Kansanen E., Kuosmanen S.M., Leinonen H., Levonen A.L. The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 2013, 1:45-49.
43. Sherratt P.J., Huang H.C., Nguyen T., Pickett C.B. Role of protein phosphorylation in the regulation of NF-E2-related factor 2 activity. Methods Enzymol. 2004, 378:286-301.
44. Adam J., Hatipoglu E., O'Flaherty L., Ternette N., Sahgal N., Lockstone H., Baban D., Nye E., Stamp G.W., Wolhuter K., Stevens M., Fischer R., Carmeliet P., Maxwell P.H., Pugh C.W., Frizzell N., Soga T., Kessler B.M., El-Bahrawy M., Ratcliffe P.J., Pollard P.J. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 2011, 20:524-537.
45. Sporn M.B., Liby K.T. NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 2012, 12:564-571.
46. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D., Forman D., Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2014 2013.
47. Kim J., Coffey D.M., Creighton C.J., Yu Z., Hawkins S.M., Matzuk M.M. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3921-3926.
48. Erickson B.K., Conner M.G., Landen C.N. The role of the fallopian tube in the origin of ovarian cancer. Am. J. Obstet. Gynecol. 2013, 209:409-414.
49. Rosen D.G., Yang G., Liu G., Mercado-Uribe I., Chang B., Xiao X.S., Zheng J., Xue F.X., Liu J. Ovarian cancer: pathology, biology, and disease models. Front. Biosci. (Landmark Ed) 2009, 14:2089-2102.
50. Gilks C.B., Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum. Pathol. 2009, 40:1213-1223.
51. Prat J. Subclassification of ovarian cancer based on pathology and genetics. Eur. J. Cancer 2009, 45(Suppl. 1):427-428.
52. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci. 2009, 100:9-16.
53. Vercellini P., Crosignani P., Somigliana E., Vigano P., Buggio L., Bolis G., Fedele L. The 'incessant menstruation' hypothesis: a mechanistic ovarian cancer model with implications for prevention. Hum. Reprod. 2011, 26:2262-2273.
54. Senthil K., Aranganathan S., Nalini N. Evidence of oxidative stress in the circulation of ovarian cancer patients. Clin. Chim. Acta 2004, 339:27-32.
55. Pylvas M., Puistola U., Kauppila S., Soini Y., Karihtala P. Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. Eur. J. Cancer 2010, 46:1661-1667.
56. Pylvas M., Puistola U., Laatio L., Kauppila S., Karihtala P. Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer. Anticancer Res. 2011, 31:1411-1415.
57. Zeller W.J., Fruhauf S., Chen G., Keppler B.K., Frei E., Kaufmann M. Chemoresistance in rat ovarian tumours. Eur. J. Cancer 1991, 27:62-67.
58. Kudoh K., Kita T., Hirata J., Ishii K., Hiramatsu H., Kikuchi Y., Nagata I. Potentiation of cisplatin sensitivity of cisplatin-resistant human ovarian cancer cell lines by l-buthionine-S, R-sulfoximine. Nippon Sanka Fujinka Gakkai Zasshi 1994, 46:525-532.
59. Akcay T., Dincer Y., Alademir Z., Aydinli K., Arvas M., Demirkiran F., Kosebay D. Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005, 119:108-113.
60. Das G.C., Bacsi A., Shrivastav M., Hazra T.K., Boldogh I. Enhanced gamma-glutamylcysteine synthetase activity decreases drug-induced oxidative stress levels and cytotoxicity. Mol. Carcinog. 2006, 45:635-647.
61. Liao H., Zhou Q., Zhang Z., Wang Q., Sun Y., Yi X., Feng Y. NRF2 is overexpressed in ovarian epithelial carcinoma and is regulated by gonadotrophin and sex-steroid hormones. Oncol. Rep. 2012, 27:1918-1924.
62. Konstantinopoulos P.A., Spentzos D., Fountzilas E., Francoeur N., Sanisetty S., Grammatikos A.P., Hecht J.L., Cannistra S.A. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res. 2011, 71:5081-5089.
63. Thu K.L., Pikor L.A., Chari R., Wilson I.M., Macaulay C.E., English J.C., Tsao M.S., Gazdar A.F., Lam S., Lam W.L., Lockwood W.W. Genetic disruption of KEAP1/CUL3 E3 ubiquitin ligase complex components is a key mechanism of NF-kappaB pathway activation in lung cancer. J. Thorac. Oncol. 2011, 6:1521-1529.
64. Kamura T., Koepp D.M., Conrad M.N., Skowyra D., Moreland R.J., Iliopoulos O., Lane W.S., Kaelin W.G., Elledge S.J., Conaway R.C., Harper J.W., Conaway J.W. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999, 284:657-661.
65. Vang R., Shih I., Kurman R.J. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv. Anat. Pathol. 2009, 16:267-282.
66. Schmeler K.M., Gershenson D.M. Low-grade serous ovarian cancer: a unique disease. Curr. Oncol. Rep. 2008, 10:519-523.
67. Sieben N.L., Macropoulos P., Roemen G.M., Kolkman-Uljee S.M., Jan Fleuren G., Houmadi R., Diss T., Warren B., Al Adnani M., De Goeij A.P., Krausz T., Flanagan A.M. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J. Pathol. 2004, 202:336-340.
68. Singer G., Oldt R., Cohen Y., Wang B.G., Sidransky D., Kurman R.J., Shih I. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 2003, 95:484-486.
69. Singer G., Stohr R., Cope L., Dehari R., Hartmann A., Cao D.F., Wang T.L., Kurman R.J., Shih I. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol. 2005, 29:218-224.
70. Salani R., Kurman R.J., Giuntoli R., Gardner G., Bristow R., Wang T.L., Shih I.M. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int. J. Gynecol. Cancer 2008, 18:487-491.
71. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
72. Cunningham J.M., Cicek M.S., Larson N.B., Davila J., Wang C., Larson M.C., Song H., Dicks E.M., Harrington P., Wick M., Winterhoff B.J., Hamidi H., Konecny G.E., Chien J., Bibikova M., Fan J.B., Kalli K.R., Lindor N.M., Fridley B.L., Pharoah P.P., Goode E.L. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci. Rep. 2014, 4:4026.
73. Buller R.E., Lallas T.A., Shahin M.S., Sood A.K., Hatterman-Zogg M., Anderson B., Sorosky J.I., Kirby P.A. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. Clin. Cancer Res. 2001, 7:831-838.
74. Forbes S., Bindal N., Bamford S., Cole C., Kok C., Beare D., Jia M., Shepherd R., Leung K., Menzies A., Teague J., Campbell P., Stratton M., Futreal P. Catalogue Of Somatic Mutations In Cancer (COSMIC) Database, Version 67, 2014 2013.
75. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
76. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., Berman K., Cobb M.H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 2001, 22:153-183.
77. Choi J.A., Kim E.Y., Song H., Kim C., Kim J.H. Reactive oxygen species are generated through a BLT2-linked cascade in Ras-transformed cells. Free Radic. Biol. Med. 2008, 44:624-634.
78. Lee A.C., Fenster B.E., Ito H., Takeda K., Bae N.S., Hirai T., Yu Z.X., Ferrans V.J., Howard B.H., Finkel T. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J. Biol. Chem. 1999, 274:7936-7940.
79. Zamkova M., Khromova N., Kopnin B.P., Kopnin P. Ras-induced ROS upregulation affecting cell proliferation is connected with cell type-specific alterations of HSF1/SESN3/p21Cip1/WAF1 pathways. Cell Cycle 2013, 12:826-836.
80. DeNicola G.M., Karreth F.A., Humpton T.J., Gopinathan A., Wei C., Frese K., Mangal D., Yu K.H., Yeo C.J., Calhoun E.S., Scrimieri F., Winter J.M., Hruban R.H., Iacobuzio-Donahue C., Kern S.E., Blair I.A., Tuveson D.A. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475:106-109.
81. Irani K., Xia Y., Zweier J.L., Sollott S.J., Der C.J., Fearon E.R., Sundaresan M., Finkel T., Goldschmidt-Clermont P.J. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 1997, 275:1649-1652.
82. Yu R., Lei W., Mandlekar S., Weber M.J., Der C.J., Wu J., Kong A.N. Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J. Biol. Chem. 1999, 274:27545-27552.
83. Yu R., Chen C., Mo Y.Y., Hebbar V., Owuor E.D., Tan T.H., Kong A.N. Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. J. Biol. Chem. 2000, 275:39907-39913.
84. Gharavi N., Haggarty S., El-Kadi A.O. Chemoprotective and carcinogenic effects of tert-butylhydroquinone and its metabolites. Curr. Drug Metab. 2007, 8:1-7.
85. Zhang D.D. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab. Rev. 2006, 38:769-789.
86. Hur W., Sun Z., Jiang T., Mason D.E., Peters E.C., Zhang D.D., Luesch H., Schultz P.G., Gray N.S. A small-molecule inducer of the antioxidant response element. Chem. Biol. 2010, 17:537-547.
87. Kensler T.W., Wakabayashi N. Nrf2: friend or foe for chemoprevention?. Carcinogenesis 2010, 31:90-99.
88. Sun Z., Huang Z., Zhang D.D. Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-dependent antioxidant response. PLoS ONE 2009, 4:e6588.
89. Sonenberg N., Hinnebusch A.G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009, 136:731-745.
90. ENCODE Project Consortium, Birney E., Stamatoyannopoulos J.A., Dutta A., Guigo R., Gingeras T.R., Margulies E.H., Weng Z., Snyder M., Dermitzakis E.T., Thurman R.E., Kuehn M.S., Taylor C.M., Neph S., Koch C.M., Asthana S., Malhotra A., Adzhubei I., Greenbaum J.A., Andrews R.M., Flicek P., Boyle P.J., Cao H., Carter N.P., Clelland G.K., Davis S., Day N., Dhami P., Dillon S.C., Dorschner M.O., Fiegler H., Giresi P.G., Goldy J., Hawrylycz M., Haydock A., Humbert R., James K.D., Johnson B.E., Johnson E.M., Frum T.T., Rosenzweig E.R., Karnani N., Lee K., Lefebvre G.C., Navas P.A., Neri F., Parker S.C., Sabo P.J., Sandstrom R., Shafer A., Vetrie D., Weaver M., Wilcox S., Yu M., Collins F.S., Dekker J., Lieb J.D., Tullius T.D., Crawford G.E., Sunyaev S., Noble W.S., Dunham I., Denoeud F., Reymond A., Kapranov P., Rozowsky J., Zheng D., Castelo R., Frankish A., Harrow J., Ghosh S., Sandelin A., Hofacker I.L., Baertsch R., Keefe D., Dike S., Cheng J., Hirsch H.A., Sekinger E.A., Lagarde J., Abril J.F., Shahab A., Flamm C., Fried C., Hackermuller J., Hertel J., Lindemeyer M., Missal K., Tanzer A., Washietl S., Korbel J., Emanuelsson O., Pedersen J.S., Holroyd N., Taylor R., Swarbreck D., Matthews N., Dickson M.C., Thomas D.J., Weirauch M.T., Gilbert J., Drenkow J., Bell I., Zhao X., Srinivasan K.G., Sung W.K., Ooi H.S., Chiu K.P., Foissac S., Alioto T., Brent M., Pachter L., Tress M.L., Valencia A., Choo S.W., Choo C.Y., Ucla C., Manzano C., Wyss C., Cheung E., Clark T.G., Brown J.B., Ganesh M., Patel S., Tammana H., Chrast J., Henrichsen C.N., Kai C., Kawai J., Nagalakshmi U., Wu J., Lian Z., Lian J., Newburger P., Zhang X., Bickel P., Mattick J.S., Carninci P., Hayashizaki Y., Weissman S., Hubbard T., Myers R.M., Rogers J., Stadler P.F., Lowe T.M., Wei C.L., Ruan Y., Struhl K., Gerstein M., Antonarakis S.E., Fu Y., Green E.D., Karaoz U., Siepel A., Taylor J., Liefer L.A., Wetterstrand K.A., Good P.J., Feingold E.A., Guyer M.S., Cooper G.M., Asimenos G., Dewey C.N., Hou M., Nikolaev S., Montoya-Burgos J.I., Loytynoja A., Whelan S., Pardi F., Massingham T., Huang H., Zhang N.R., Holmes I., Mullikin J.C., Ureta-Vidal A., Paten B., Seringhaus M., Church D., Rosenbloom K., Kent W.J., Stone E.A., NISC Comparative Sequencing Program, Baylor College of Medicine Human Genome Sequencing Center, Washington University Genome Sequencing Center, Broad Institute, Children's Hospital Oakland Research Institute, Batzoglou S., Goldman N., Hardison R.C., Haussler D., Miller W., Sidow A., Trinklein N.D., Zhang Z.D., Barrera L., Stuart R., King D.C., Ameur A., Enroth S., Bieda M.C., Kim J., Bhinge A.A., Jiang N., Liu J., Yao F., Vega V.B., Lee C.W., Ng P., Shahab A., Yang A., Moqtaderi Z., Zhu Z., Xu X., Squazzo S., Oberley M.J., Inman D., Singer M.A., Richmond T.A., Munn K.J., Rada-Iglesias A., Wallerman O., Komorowski J., Fowler J.C., Couttet P., Bruce A.W., Dovey O.M., Ellis P.D., Langford C.F., Nix D.A., Euskirchen G., Hartman S., Urban A.E., Kraus P., Van Calcar S., Heintzman N., Kim T.H., Wang K., Qu C., Hon G., Luna R., Glass C.K., Rosenfeld M.G., Aldred S.F., Cooper S.J., Halees A., Lin J.M., Shulha H.P., Zhang X., Xu M., Haidar J.N., Yu Y., Ruan Y., Iyer V.R., Green R.D., Wadelius C., Farnham P.J., Ren B., Harte R.A., Hinrichs A.S., Trumbower H., Clawson H., Hillman-Jackson J., Zweig A.S., Smith K., Thakkapallayil A., Barber G., Kuhn R.M., Karolchik D., Armengol L., Bird C.P., de Bakker P.I., Kern A.D., Lopez-Bigas N., Martin J.D., Stranger B.E., Woodroffe A., Davydov E., Dimas A., Eyras E., Hallgrimsdottir I.B., Huppert J., Zody M.C., Abecasis G.R., Estivill X., Bouffard G.G., Guan X., Hansen N.F., Idol J.R., Maduro V.V., Maskeri B., McDowell J.C., Park M., Thomas P.J., Young A.C., Blakesley R.W., Muzny D.M., Sodergren E., Wheeler D.A., Worley K.C., Jiang H., Weinstock G.M., Gibbs R.A., Graves T., Fulton R., Mardis E.R., Wilson R.K., Clamp M., Cuff J., Gnerre S., Jaffe D.B., Chang J.L., Lindblad-Toh K., Lander E.S., Koriabine M., Nefedov M., Osoegawa K., Yoshinaga Y., Zhu B., de Jong P.J. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007, 447:799-816.
91. Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., Horowitz I.R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 2003, 21:283-290.
92. Lanitis E., Dangaj D., Hagemann I.S., Song D.G., Best A., Sandaltzopoulos R., Coukos G., Powell D.J. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS ONE 2012, 7:e49829.
93. Natali P.G., Nicotra M.R., Bigotti A., Venturo I., Slamon D.J., Fendly B.M., Ullrich A. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int. J. Cancer 1990, 45:457-461.
94. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
95. Felip E., Del Campo J.M., Rubio D., Vidal M.T., Colomer R., Bermejo B. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 1995, 75:2147-2152.
96. Pietras R.J., Fendly B.M., Chazin V.R., Pegram M.D., Howell S.B., Slamon D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994, 9:1829-1838.
97. Juhl H., Downing S.G., Wellstein A., Czubayko F. HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting. J. Biol. Chem. 1997, 272:29482-29486.
98. Alaoui-Jamali M.A., Paterson J., Al Moustafa A.E., Yen L. The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem. Cell Biol. 1997, 75:315-325.
99. Reese D.M., Slamon D.J. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 1997, 15:1-8.
100. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
101. Levin W. Transcriptional Activation in Response to the HER-2/neu Stimulatory Ligand Heregulin and Inhibitory Antibody 4D5 in Human Breast Cancer Cells 1995, (Master's Thesis), University of California, Los Angeles.
102. Naderi A., Liu J., Francis G.D. A feedback loop between BEX2 and ErbB2 mediated by c-Jun signaling in breast cancer. Int. J. Cancer 2012, 130:71-82.
103. Kang K.W., Cho M.K., Lee C.H., Kim S.G. Activation of phosphatidylinositol 3-kinase and Akt by tert-butylhydroquinone is responsible for antioxidant response element-mediated rGSTA2 induction in H4IIE cells. Mol. Pharmacol. 2001, 59:1147-1156.
104. Martin D., Rojo A.I., Salinas M., Diaz R., Gallardo G., Alam J., De Galarreta C.M., Cuadrado A. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J. Biol. Chem. 2004, 279:8919-8929.
105. Wang L., Chen Y., Sternberg P., Cai J. Essential roles of the PI3 kinase/Akt pathway in regulating Nrf2-dependent antioxidant functions in the RPE. Invest. Ophthalmol. Vis. Sci. 2008, 49:1671-1678.
106. Crabb S., Hayden A., Gould K., Andrews L., Packham G. Investigating the Nrf2 transcription factor as a regulator of cisplatin resistance in urothelial carcinoma (UC) cells. Genitourinary Cancers Symposium - Abstract 256 29 2011.
107. Pitha-Rowe I., Liby K., Royce D., Sporn M. Synthetic triterpenoids attenuate cytotoxic retinal injury: cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN. Invest. Ophthalmol. Vis. Sci. 2009, 50:5339-5347.
108. Rojo A.I., Rada P., Mendiola M., Ortega-Molina A., Wojdyla K., Rogowska-Wrzesinska A., Hardisson D., Serrano M., Cuadrado A. The PTEN/NRF2 axis promotes human carcinogenesis. Antioxid. Redox Signal. Jul 31 2014, (Epub ahead of print).
109. Cohen P., Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2001, 2:769-776.
110. Jain A.K., Jaiswal A.K. GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J. Biol. Chem. 2007, 282:16502-16510.
111. Kang K.W., Lee S.J., Park J.W., Kim S.G. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. Mol. Pharmacol. 2002, 62:1001-1010.
112. Pal T., Permuth-Wey J., Betts J.A., Krischer J.P., Fiorica J., Arango H., LaPolla J., Hoffman M., Martino M.A., Wakeley K., Wilbanks G., Nicosia S., Cantor A., Sutphen R. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005, 104:2807-2816.
113. Campeau P.M., Foulkes W.D., Tischkowitz M.D. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum. Genet. 2008, 124:31-42.
114. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., Bussaglia E., Prat J., Harkes I.C., Repasky E.A., Gabrielson E., Schutte M., Baylin S.B., Herman J.G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 2000, 92:564-569.
115. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
116. Gorrini C., Baniasadi P.S., Harris I.S., Silvester J., Inoue S., Snow B., Joshi P.A., Wakeham A., Molyneux S.D., Martin B., Bouwman P., Cescon D.W., Elia A.J., Winterton-Perks Z., Cruickshank J., Brenner D., Tseng A., Musgrave M., Berman H.K., Khokha R., Jonkers J., Mak T.W., Gauthier M.L. BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J. Exp. Med. 2013, 210:1529-1544.
117. Gorrini C., Gang B.P., Bassi C., Wakeham A., Baniasadi S.P., Hao Z., Li W.Y., Cescon D.W., Li Y.T., Molyneux S., Penrod N., Lupien M., Schmidt E.E., Stambolic V., Gauthier M.L., Mak T.W. Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:4472-4477.
118. Symonds D.A., Merchenthaler I., Flaws J.A. Methoxychlor and estradiol induce oxidative stress DNA damage in the mouse ovarian surface epithelium. Toxicol. Sci. 2008, 105:182-187.
119. Fussell K.C., Udasin R.G., Smith P.J., Gallo M.A., Laskin J.D. Catechol metabolites of endogenous estrogens induce redox cycling and generate reactive oxygen species in breast epithelial cells. Carcinogenesis 2011, 32:1285-1293.
120. Cavalieri E., Frenkel K., Liehr J.G., Rogan E., Roy D. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J. Natl. Cancer Inst. Monogr. 2000, 27:75-93.
121. Ansell P.J., Lo S.C., Newton L.G., Espinosa-Nicholas C., Zhang D.D., Liu J.H., Hannink M., Lubahn D.B. Repression of cancer protective genes by 17beta-estradiol: ligand-dependent interaction between human Nrf2 and estrogen receptor alpha. Mol. Cell. Endocrinol. 2005, 243:27-34.
122. Yao Y., Brodie A.M., Davidson N.E., Kensler T.W., Zhou Q. Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res. Treat. 2010, 124:585-591.
123. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lonning P.E., Brown P.O., Borresen-Dale A.L., Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8418-8423.
124. Foulkes W.D., Brunet J.S., Stefansson I.M., Straume O., Chappuis P.O., Begin L.R., Hamel N., Goffin J.R., Wong N., Trudel M., Kapusta L., Porter P., Akslen L.A. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004, 64:830-835.
125. Lakhani S.R., Van De Vijver M.J., Jacquemier J., Anderson T.J., Osin P.P., McGuffog L., Easton D.F. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 2002, 20:2310-2318.
126. Tung N., Wang Y., Collins L.C., Kaplan J., Li H., Gelman R., Comander A.H., Gallagher B., Fetten K., Krag K., Stoeckert K.A., Legare R.D., Sgroi D., Ryan P.D., Garber J.E., Schnitt S.J. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res. 2010, 12:R12.
127. Aghmesheh M., Edwards L., Clarke C.L., Byth K., Katzenellenbogen B.S., Russell P.J., Friedlander M., Tucker K.M., de Fazio A. Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. Gynecol. Oncol. 2005, 97:16-25.
128. Ansell P.J., Espinosa-Nicholas C., Curran E.M., Judy B.M., Philips B.J., Hannink M., Lubahn D.B. In vitro and in vivo regulation of antioxidant response element-dependent gene expression by estrogens. Endocrinology 2004, 145:311-317.
129. Simpson E.R. Sources of estrogen and their importance. J. Steroid Biochem. Mol. Biol. 2003, 86:225-230.
130. Singh B., Shoulson R., Chatterjee A., Ronghe A., Bhat N.K., Dim D.C., Bhat H.K. Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways. Carcinogenesis 2014, 35:1872-1880.
131. Ahmed A.A., Etemadmoghadam D., Temple J., Lynch A.G., Riad M., Sharma R., Stewart C., Fereday S., Caldas C., Defazio A., Bowtell D., Brenton J.D. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 2010, 221:49-56.
132. Brachova P., Thiel K.W., Leslie K.K. The consequence of oncomorphic TP53 mutations in ovarian cancer. Int. J. Mol. Sci. 2013, 14:19257-19275.
133. Zilfou J.T., Lowe S.W. Tumor suppressive functions of p53. Cold Spring Harb Perspect. Biol. 2009, 1:a001883.
134. Moll U.M., Petrenko O. The MDM2-p53 interaction. Mol. Cancer Res. 2003, 1:1001-1008.
135. Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., Chumakov P.M. The antioxidant function of the p53 tumor suppressor. Nat. Med. 2005, 11:1306-1313.
136. Pani G., Galeotti T. Role of MnSOD and p66shc in mitochondrial response to p53. Antioxid. Redox Signal. 2011, 15:1715-1727.
137. Shin B.Y., Jin S.H., Cho I.J., Ki S.H. Nrf2-ARE pathway regulates induction of sestrin-2 expression. Free Radic. Biol. Med. 2012, 53:834-841.
138. Gartel A.L., Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 2002, 1:639-649.
139. Chen W., Sun Z., Wang X.J., Jiang T., Huang Z., Fang D., Zhang D.D. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol. Cell 2009, 34:663-673.
140. Haupt S., Berger M., Goldberg Z., Haupt Y. Apoptosis - the p53 network. J. Cell Sci. 2003, 116:4077-4085.
141. Faraonio R., Vergara P., Di Marzo D., Pierantoni M.G., Napolitano M., Russo T., Cimino F. p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J. Biol. Chem. 2006, 281:39776-39784.
142. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., Vogelstein B. A model for p53-induced apoptosis. Nature 1997, 389:300-305.
143. Vousden K.H. P53: death star. Cell 2000, 103:691-694.
144. Asher G., Lotem J., Cohen B., Sachs L., Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1188-1193.
145. You A., Nam C.W., Wakabayashi N., Yamamoto M., Kensler T.W., Kwak M.K. Transcription factor Nrf2 maintains the basal expression of Mdm2: an implication of the regulation of p53 signaling by Nrf2. Arch. Biochem. Biophys. 2011, 507:356-364.
146. Bae I., Fan S., Meng Q., Rih J.K., Kim H.J., Kang H.J., Xu J., Goldberg I.D., Jaiswal A.K., Rosen E.M. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res. 2004, 64:7893-7909.
147. Sasaki H., Suzuki A., Shitara M., Okuda K., Hikosaka Y., Moriyama S., Yano M., Fujii Y. Mutations in lung cancer patients. Oncol. Lett. 2013, 6:719-721.
148. Berkenblit A., Cannistra S.A. Advances in the management of epithelial ovarian cancer. J. Reprod. Med. 2005, 50:426-438.
149. Banerjee S., Kaye S. The role of targeted therapy in ovarian cancer. Eur. J. Cancer 2011, 47(Suppl. 3):S116-S130.
150. Lee J.M., Li J., Johnson D.A., Stein T.D., Kraft A.D., Calkins M.J., Jakel R.J., Johnson J.A. Nrf2, a multi-organ protector?. FASEB J. 2005, 19:1061-1066.
151. Florczyk U., Jazwa A., Maleszewska M., Mendel M., Szade K., Kozakowska M., Grochot-Przeczek A., Viscardi M., Czauderna S., Bukowska-Strakova K., Kotlinowski J., Jozkowicz A., Loboda A., Dulak J. Nrf2 regulates angiogenesis: effect on endothelial cells, bone marrow-derived proangiogenic cells and hind limb ischemia. Antioxid. Redox Signal. 2014, 20:1693-1708.
152. Cuadrado A., Martin-Moldes Z., Ye J., Lastres-Becker I. Transcription factors NRF2 and NF-kappaB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation. J. Biol. Chem. 2014, 289:15244-15258.
153. Jin W., Wang H., Ji Y., Hu Q., Yan W., Chen G., Yin H. Increased intestinal inflammatory response and gut barrier dysfunction in Nrf2-deficient mice after traumatic brain injury. Cytokine 2008, 44:135-140.
154. Hayes J.D., Dinkova-Kostova A.T. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 2014, 39:199-218.
155. Heiss E.H., Schachner D., Zimmermann K., Dirsch V.M. Glucose availability is a decisive factor for Nrf2-mediated gene expression. Redox Biol. 2013, 1:359-365.
156. Tsai J.J., Dudakov J.A., Takahashi K., Shieh J.H., Velardi E., Holland A.M., Singer N.V., West M.L., Smith O.M., Young L.F., Shono Y., Ghosh A., Hanash A.M., Tran H.T., Moore M.A., van den Brink M.R. Nrf2 regulates haematopoietic stem cell function. Nat. Cell Biol. 2013, 15:309-316.
157. Homma S., Ishii Y., Morishima Y., Yamadori T., Matsuno Y., Haraguchi N., Kikuchi N., Satoh H., Sakamoto T., Hizawa N., Itoh K., Yamamoto M. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin. Cancer Res. 2009, 15:3423-3432.
158. Lister A., Nedjadi T., Kitteringham N.R., Campbell F., Costello E., Lloyd B., Copple I.M., Williams S., Owen A., Neoptolemos J.P., Goldring C.E., Park B.K. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol. Cancer 2011, 10. (37-4598-10-37).
159. Ma X., Zhang J., Liu S., Huang Y., Chen B., Wang D. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer. Cancer Chemother. Pharmacol. 2012, 69:485-494.
160. Singh A., Boldin-Adamsky S., Thimmulappa R.K., Rath S.K., Ashush H., Coulter J., Blackford A., Goodman S.N., Bunz F., Watson W.H., Gabrielson E., Feinstein E., Biswal S. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 2008, 68:7975-7984.
161. Kim T.H., Hur E.G., Kang S.J., Kim J.A., Thapa D., Lee Y.M., Ku S.K., Jung Y., Kwak M.K. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Cancer Res. 2011, 71:2260-2275.
162. Wang X.J., Sun Z., Villeneuve N.F., Zhang S., Zhao F., Li Y., Chen W., Yi X., Zheng W., Wondrak G.T., Wong P.K., Zhang D.D. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008, 29:1235-1243.
163. Cho J.M., Manandhar S., Lee H.R., Park H.M., Kwak M.K. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett. 2008, 260:96-108.
164. Kang K.A., Piao M.J., Kim K.C., Kang H.K., Chang W.Y., Park I.C., Keum Y.S., Surh Y.J., Hyun J.W. Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation. Cell. Death Dis. 2014, 5:e1183.
165. Cao B., Que L., Zhang Y., Chen S., Yin W., Wang S., Ma L., Yu S. Association analysis of the expression level of Nrf2 mRNA in peripheral blood nucleated cells and the severity of chemotherapy-induced myelosuppression. Tumor 2012, 32:124-129.
166. Ren D., Villeneuve N.F., Jiang T., Wu T., Lau A., Toppin H.A., Zhang D.D. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1433-1438.
167. Ohnuma T., Matsumoto T., Itoi A., Kawana A., Nishiyama T., Ogura K., Hiratsuka A. Enhanced sensitivity of A549 cells to the cytotoxic action of anticancer drugs via suppression of Nrf2 by procyanidins from Cinnamomi cortex extract. Biochem. Biophys. Res. Commun. 2011, 413:623-629.
168. Zhuang M., Jiang H., Suzuki Y., Li X., Xiao P., Tanaka T., Ling H., Yang B., Saitoh H., Zhang L., Qin C., Sugamura K., Hattori T. Procyanidins and butanol extract of Cinnamomi cortex inhibit SARS-CoV infection. Antiviral Res. 2009, 82:73-81.
169. Hall I.H., Lee K.H., Eigebaly S.A., Imakura Y., Sumida Y., Wu R.Y. Antitumor agents. XXXIV: mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells. J. Pharm. Sci. 1979, 68:883-887.
170. Cuendet M., Gills J.J., Pezzuto J.M. Brusatol-induced HL-60 cell differentiation involves NF-kappaB activation. Cancer Lett. 2004, 206:43-50.
171. Gommans W.M., Haisma H.J., Rots M.G. Engineering zinc finger protein transcription factors: the therapeutic relevance of switching endogenous gene expression on or off at command. J. Mol. Biol. 2005, 354:507-519.
172. de Groote M.L., Verschure P.J., Rots M.G. Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res. 2012, 40:10596-10613.
173. Pál C., Hurst L. Chapter 16: epigenetic inheritance and evolutionary adaptation. Organelles, Genomes and Eukaryote Phylogeny: An Evolutionary Synthesis in the Age of Genomics 2004, 347-364. CRC Press. R. Hirt, D. Horner (Eds.).
174. Falahi F., Huisman C., Kazemier H.G., van der Vlies P., Kok K., Hospers G.A., Rots M.G. Towards sustained silencing of HER2/neu in cancer by epigenetic editing. Mol. Cancer Res. 2013, 11:1029-1039.
175. Rivenbark A.G., Stolzenburg S., Beltran A.S., Yuan X., Rots M.G., Strahl B.D., Blancafort P. Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics 2012, 7:350-360.
176. Snowden A.W., Gregory P.D., Case C.C., Pabo C.O. Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. Curr. Biol. 2002, 12:2159-2166.
177. Konermann S., Brigham M.D., Trevino A.E., Hsu P.D., Heidenreich M., Cong L., Platt R.J., Scott D.A., Church G.M., Zhang F. Optical control of mammalian endogenous transcription and epigenetic states. Nature 2013, 500:472-476.
178. Mendenhall E.M., Williamson K.E., Reyon D., Zou J.Y., Ram O., Joung J.K., Bernstein B.E. Locus-specific editing of histone modifications at endogenous enhancers. Nat. Biotechnol. 2013, 31:1133-1136.
179. Chen H., Kazemier H.G., de Groote M.L., Ruiters M.H., Xu G.L., Rots M.G. Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter. Nucleic Acids Res. 2014, 42:1563-1574.
180. Gregory D.J., Zhang Y., Kobzik L., Fedulov A.V. Specific transcriptional enhancement of inducible nitric oxide synthase by targeted promoter demethylation. Epigenetics 2013, 8:1205-1212.
181. Maeder M.L., Angstman J.F., Richardson M.E., Linder S.J., Cascio V.M., Tsai S.Q., Ho Q.H., Sander J.D., Reyon D., Bernstein B.E., Costello J.F., Wilkinson M.F., Joung J.K. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat. Biotechnol. 2013, 31:1137-1142.
182. Rusk N. CRISPRs and epigenome editing. Nat. Methods 2014, 11:28.
183. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control. Release 2012, 161:175-187.
184. van der Gun B.T., Wasserkort R., Monami A., Jeltsch A., Rasko T., Slaska-Kiss K., Cortese R., Rots M.G., de Leij L.F., Ruiters M.H., Kiss A., Weinhold E., McLaughlin P.M. Persistent downregulation of the pancarcinoma-associated epithelial cell adhesion molecule via active intranuclear methylation. Int. J. Cancer 2008, 123:484-489.
185. Kowalski P.S., Zwiers P.J., Morselt H.W., Kuldo J.M., Leus N.G., Ruiters M.H., Molema G., Kamps J.A. Anti-VCAM-1 SAINT-O-Somes enable endothelial-specific delivery of siRNA and downregulation of inflammatory genes in activated endothelium in vivo. J. Control. Release 2014, 176:64-75.
186. Rosen E.M., Pishvaian M.J. Targeting the BRCA1/2 tumor suppressors. Curr. Drug Targets 2014, 15:17-31.
187. McGlynn P., Lloyd R.G. Recombinational repair and restart of damaged replication forks. Nat. Rev. Mol. Cell Biol. 2002, 3:859-870.
188. Morales J., Li L., Fattah F., Dong Y., Bey E., Patel M., Gao J., Boothman D. Review of poly (ADP-Ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases 2013, 23:195-208.
189. He J.X., Yang C.H., Miao Z.H. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacol. Sin. 2010, 31:1172-1180.
190. Kryston T.B., Georgiev A.B., Pissis P., Georgakilas A.G. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat. Res. 2011, 711:193-201.
191. Righetti S.C., Della Torre G., Pilotti S., Menard S., Ottone F., Colnaghi M.I., Pierotti M.A., Lavarino C., Cornarotti M., Oriana S., Bohm S., Bresciani G.L., Spatti G., Zunino F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 1996, 56:689-693.
192. Reles A., Wen W.H., Schmider A., Gee C., Runnebaum I.B., Kilian U., Jones L.A., El-Naggar A., Minguillon C., Schonborn I., Reich O., Kreienberg R., Lichtenegger W., Press M.F. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res. 2001, 7:2984-2997.
193. Sarafian T.A., Bredesen D.E. Is apoptosis mediated by reactive oxygen species?. Free Radic. Res. 1994, 21:1-8.
194. Singh B., Chatterjee A., Ronghe A.M., Bhat N.K., Bhat H.K. Antioxidant-mediated up-regulation of OGG1 via NRF2 induction is associated with inhibition of oxidative DNA damage in estrogen-induced breast cancer. BMC Cancer 2013, 13. (253-2407-13-253).
195. Kim S.B., Pandita R.K., Eskiocak U., Ly P., Kaisani A., Kumar R., Cornelius C., Wright W.E., Pandita T.K., Shay J.W. Targeting of Nrf2 induces DNA damage signaling and protects colonic epithelial cells from ionizing radiation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E2949-E2955.
196. Mitsuishi Y., Taguchi K., Kawatani Y., Shibata T., Nukiwa T., Aburatani H., Yamamoto M., Motohashi H. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 2012, 22:66-79.
197. Zhou S., Ye W., Zhang M., Liang J. The effects of nrf2 on tumor angiogenesis: a review of the possible mechanisms of action. Crit. Rev. Eukaryot. Gene Expr. 2012, 22:149-160.
198. Konstantinopoulos P.A., Fountzilas E., Pillay K., Zerbini L.F., Libermann T.A., Cannistra S.A., Spentzos D. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med. Genet. 2008, 1. (59-8794-1-59).